July 26-30, Amsterdam, Netherlands
COVID-19 (Novel Coronavirus) Updates: For the latest information on the status of AAIC, policies and how to reach us, visit our COVID-19 updates page.
Scientific Sessions
On This Page:
Plenary Sessions
The schedule below reflects the invited program only. The complete schedule, including the submitted program, will be available closer to the conference.
10:30 - 11:15 a.m.
Association Welcome
11:15 - 11:45 a.m.
Imaging Biomarkers and Alzheimer's Disease Prevention
Helen Wills Neuroscience Institute, University of California, Berkeley, United States
Theme: Biomarkers
Session: PL-01-02
10:30 - 11 a.m.
Proteostasis/Autophagy
Nathan S. Kline Institute for Psychiatric Research; NYU Langone Medical Center, United States
Theme: Basic Science and Pathogenesis
Session: PL-02-01
11 - 11:30 a.m.
Global Guidelines for Dementia Risk Reduction
UNSW Ageing Futures Institute; NeuRA; ARC Centre of Excellence in Population Ageing Research; NHMRC Dementia Centre for Research Collaboration, Australia
Theme: Dementia Care and Psychosocial Factors and Public Health
Session: PL-02-02
10:30 - 11 a.m.
To Be Announced
11 - 11:30 a.m.
Epidemiology of Dementia in Diverse Populations
Rush Alzheimer’s Disease Center, United States
Theme: Dementia Care and Psychosocial Factors and Public Health
Session: PL-03-02
10:30 - 11 a.m.
The Two Indias
Indian Institute of Science, India
Theme: Basic Science and Pathogenesis
Session: PL-04-01
11 - 11:30 a.m.
To Be Announced
10:30 - 11 a.m.
Blood Based Biomarkers
Amsterdam UMC, Netherlands
Theme: Biomarkers
Session: PL-05-01
11 - 11:30 a.m.
Mechanisms of Neurovascular Dysfunction and Interaction With Alzheimer's Disease Pathology
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, United States
Theme: Clinical Manifestations
Session: PL-05-02
Symposium Sessions
-
Dementia and Cognitive Health in LGBTQ Older Adults [S1-01]
8 – 9:30 a.m.
Theme: Public Health | Topic: Epidemiology
PRESENTATIONS
SPEAKERS
Interventions for LGBTQ Older Adults With ADRD and Their Care Partners [S1-01-01]
Karen Fredriksen-Goldsen
University of Washington, United States
The Epidemiology of ADRD in LGBTQ Older Adults [S1-01-02]
Jason Flatt
University of California, San Francisco, United States
LGBTQ Older Adults With Cognitive Impairment: Implications for Early Diagnosis, Treatment and Care [S1-01-03]
Sue Westwood
University of York, United Kingdom
To Be Announced [S1-01-04]
To Be Announced
-
Immunity in the Aging or Diseased Brain [S1-02]
8 - 9:30 a.m.
Theme: Basic and Science Pathogenesis | Topic: Human Neuropathology
PRESENTATIONS
SPEAKERS
To Be Announced [S1-02-01]
To Be Announced
To Be Announced [S1-02-02]
To Be Announced
Microglia Depletion/Repopulation [S1-02-03]
Kim Green
University of California, Irvine, United States
Microglial Immune Memory [S1-02-04]
Jonas Neher
Research Institute in Tübingen, Germany
-
Ethics in Dementia [S2-01]
8 – 9:30 a.m.
Theme: Clinical Manifestations | Topic: Neuropsychiatry and Behavioral Neurology
PRESENTATIONS
SPEAKERS
APOE Disclosure: One Investigator of the REVEAL Study [S2-01-01]
J. Scott Roberts
University of Michigan, United States
Expectations and Effects of Biomarker-Based Dementia Risk Prediction in MCI – The PreDaDQual Project [S2-01-02]
Ayda Rostamzadeh
University Hospital of Cologne, Germany
Communication of Risk for Dementia in MCI – The ABIDE Project [S2-01-03]
Jetske van der Schaar
VU Medical Center, Netherlands
Amyloid Disclosure in Mild Cognitive Impairment [S2-01-04]
Jennifer Lingler
University of Pittsburgh, United States
-
Measuring Tau Accumulation And Progression [S2-02]
8 - 9:30 a.m.
Theme: Biomarkers | Topic: Biomarkers (Non-Neuroimaging)
PRESENTATIONS
SPEAKERS
Tau Progression Evidence From Tau PET Imaging [S2-02-01]
Rik Ossenkoppele
Alzheimer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands; Lund University, Sweden
To Be Announced [S2-02-02]
To Be Announced
Genetics of Tau Accumulation and Progression [S2-02-03]
Philip De Jager
Broad Institute of MIT and Harvard, United States
Interaction of Tau With Other Pathologies [S2-02-04]
Virginia Lee
University of Pennsylvania, United States
-
Using Technology to Assess Cognition in the Community [S3-01]
8 – 9:30 a.m.
Theme: Clinical Manifestations | Topic: Neuropsychology
PRESENTATIONS
SPEAKERS
Unsupervised Online Neuropsychological Testing – The Principles [S3-01-01]
Paul Maruff
The Florey Institute of Neuroscience and Mental Health, Australia
To Be Announced [S3-01-02]
To Be Announced
Technology to Enhance Social Stimulation and Reduce Problem Behaviors [S3-01-03]
Jesus Favela
CICESE Research Center, Mexico
Testing on Mobile Devices [S3-01-04]
Simon Collinson
Savonix, Singapore
-
Toward a Precision Medicine Approach in Alzheimer’s Disease [S3-02]
8 - 9:30 a.m.
Theme: Biomarkers | Topic: Biomarkers (Non-Neuroimaging)
PRESENTATIONS
SPEAKERS
Blood-Based Biomarkers to Predict Current and Future Brain Amyloidosis [S3-02-01]
Randall Bateman
Knight Alzheimer Disease Research Center, United States
Accurate Prediction of β-Amyloid Positivity Using Risk Models and Plasma Aβ and P-tau Analyses [S3-02-02]
Sebastian Palmqvist
Lund University, Sweden
Biomarker-Based Prognosis for People With Mild Cognitive Impairment [S3-02-03]
Ingrid Van Maurik
Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands
Organizing Mechanistic Knowledge About Neurodegenerative Diseases for the Improvement of Drug Development and Therapy [S3-02-04]
Martin Hofmann-Apitius
Fraunhofer Institute for Algorithms and Scientific Computing SCAI, Germany
-
Repurposing Drugs Targeting Glia and Inflammatory Mechanisms [S4-01]
8 – 9:30 a.m.
Theme: Drug Development | Topic: Human
PRESENTATIONS
SPEAKERS
Role of Inflammatory Cells in Neurodegeneration [S4-01-01]
Malu Tansey
Emory University, United States
Senolytic Therapies Targeting Oligodendrocyte Precursor Cells [S4-01-02]
Howard Fillit
The Alzheimer’s Drug Discovery Foundation, United States
Microglial Cells in AD: Good Guys or Bad Guys? [S4-01-03]
Knut Biber
AbbVie Deutschland GmbH & Co. KG, Germany
To Be Announced [S4-01-04]
To Be Announced
-
Repurposing Drugs Targeting Glia and Inflammatory Mechanisms [S5-01]
8 – 9:30 a.m.
Theme: Drug Development | Topic: Human
PRESENTATIONS
SPEAKERS
Amyloid-Related Imaging Abnormalities (ARIA) [S5-01-01]
James Nicoll
University Hospital Southampton NHS Foundation Trust, United Kingdom
Cerebrovascular Disease [S5-01-02]
Donna Wilcock
University of Kentucky, United States
Trauma-Related Axonal Damage [S5-01-03]
Victoria Johnson
University of Pennsylvania, United States
Neuroimaging of White Matter Hyperintensities (WMH) [S5-01-04]
Joanna Wardlaw
University of Edinburgh, United Kingdom
Become an ISTAART Member
ISTAART members receive discounted registration rates and access to exclusive events at AAIC. Join today for these benefits and much more.
lg > 992px
md > 768px
sm < 767px
xs
Join the Conversation #AAIC20